Newron Pharmaceuticals S.p.A. (NWPHF)
| Market Cap | 301.59M +63.2% |
| Revenue (ttm) | 22.46M -62.8% |
| Net Income | -15.54M |
| EPS | -0.78 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 101 |
| Open | 20.00 |
| Previous Close | n/a |
| Day's Range | 20.00 - 20.00 |
| 52-Week Range | 20.00 - 20.00 |
| Beta | 0.72 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 22, 2026 |
About Newron Pharmaceuticals
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl... [Read more]
News
Newron Provides Update Following Type A Meeting With the FDA
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with...
Newron Pharmaceuticals to Participate in June Investor Conferences
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #Biotech--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapie...
Newron Pharma price target lowered to CHF 44 from CHF 48 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Newron Pharma (NWPHF) to CHF 44 from CHF 48 and keeps a Buy rating on the shares.
Newron Pharma price target raised to CHF 48 from CHF 43 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Newron Pharma (NWPHF) to CHF 48 from CHF 43 and keeps a Buy rating on the shares. The firm…
Newron Pharmaceuticals Transcript: 38th Annual Roth Conference
A novel add-on therapy for treatment-resistant schizophrenia is advancing through three pivotal global studies, showing sustained efficacy and a unique mechanism targeting hippocampal hyperexcitability. Regulatory submission is expected within 12–15 months, with strong physician interest and no direct competition in its segment.
Newron Pharmaceuticals Earnings Call Transcript: H2 2025
Achieved major milestones with pivotal phase III studies for evenamide, strong financial position, and new IP protection. Results expected by end of 2026 will support NDA submission, with additional funding and NASDAQ uplisting preparations underway.
Newron Pharmaceuticals Annual report: H2 2025
Newron Pharmaceuticals has published its H2 2025 annual report on March 24, 2026.
Newron Pharmaceuticals Slides: H2 2025
Newron Pharmaceuticals has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 24, 2026.
Newron Pharmaceuticals Earnings release: H2 2025
Newron Pharmaceuticals released its H2 2025 earnings on March 24, 2026, summarizing the period's financial results.
Newron Presents 2025 Financial Results and Provides 2026 Outlook
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron today announced its financial results and operational highlights for the business year ended Dec. 31, 2025, and provided an o...
Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel th...
Newron Announces Agreement With the European Investment Bank (EIB) to Extend the Near-Term Tranche Repayment Dates of Its 2018 Finance Contract
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finan...
Newron Announces Nominations to Its Board of Directors at Upcoming Annual General Meeting
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron announces nominations to its Board of Directors at its upcoming Annual General Meeting.
Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
MILAN, Italy & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron secures up to EUR 38 million to advance Phase III Evenamide program as potential first add-on therapy for treatment-re...
Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals notes new publication highlighting clinically meaningful benefits of evenamide as an adjunctive treatment in ...
Newron Pharma price target raised to CHF 43 from CHF 26 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Newron Pharma (NWPHF) to CHF 43 from CHF 26 and keeps a Buy rating on the shares. The firm…
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron's partner EA Pharma Co., Ltd. announces today the initiation of its Phase III clinical trial with evenamide in Japan.
Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals further expands its intellectual property portfolio for Evenamide with a new EU composition of matter patent.
Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week
MORRISTOWN, N.J. & MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron will host investor and partnering meetings on January 12-14, 2026, coinciding with the 44th Annual J.P. Morgan Conference in ...
Newron Pharma initiated with a Buy at Lucid Capital
Lucid Capital analyst Elemer Piros initiated coverage of Newron Pharma (NWPHF) with a Buy rating and CHF 73 price target The firm says Newron is developing a first-in-class drug, evenamide…
Newron Announces the US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS)
MORRISTOWN, N.J. & MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron announces US initiation of its ENIGMA-TRS 2 Phase III global study of evenamide for patients with treatment-resistant schizop...
Newron Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Newron Pharma (NWPHF) with a Buy rating and CHF 26 price target The company is advancing a “paradigm-shifting” approach to addressing treatment-resistant schizoph...
Newron Pharmaceuticals Slides: Company presentation
Newron Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on November 24, 2025.
Newron to Present New Analyses From and Updates on its Clinical Program Evaluating Evenamide as an Add-on Treatment for Schizophrenia at the 38th European College of Neuropsychopharmacology (ECNP) Congress 2025
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron to present new analyses on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the ECNP Congress 2025.
Newron presents H1 2025 results and provides business update
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals today announced its financial results and operational highlights for the half-year ended June 30, 2025.